Patient characteristics and outcomes (n=12)
| Median age | 64 years |
| N (%) | |
| Female | 8 (66.7) |
| White race | 11 (91.7) |
| Diagnosis | |
| Vasculitis | 8 |
| Rheumatoid arthritis | 2 |
| Other* | 2 |
| Comorbidities | |
| Body Mass Index 30+ | 5 (41.7) |
| Heart disease† | 6 (50.0) |
| Diabetes | 2 (16.7) |
| Pulmonary‡ | 5 (41.7) |
| Chronic kidney disease | 3 (25.0) |
| Malignancy | 1 (8.3) |
| Concomitant immunosuppression | |
| Glucocorticoid<10 mg/day | 4 (33.3) |
| Glucocorticoid≥10 mg/day | 1 (8.3) |
| Methotrexate | 1 (8.3) |
| Mycophenolate mofetil | 4 (33.3) |
| Duration of rituximab | |
| 1–3 years | 3 (25.0) |
| >3 years | 9 (75.0) |
| History of prior COVID-19 | 2 (16.7) |
| Outcomes in all patients§ | |
| NIH COVID ordinal scale 1–3 | 11 |
| NIH COVID ordinal scale 4–8 | 1 |
| Outcomes (treated with mAb¶) | |
| NIH 1–3 | 8 |
| NIH 4–8 | 0 |
| Outcomes (treated with nirmatrelvir/ritonavir) | |
| NIH 1–3 | 2 |
| NIH 4–8 | 0 |
*Antisynthetase syndrome, scleroderma.
†Hypertension, coronary artery disease, congestive heart failure.
‡Chronic obstructive pulmonary disease, asthma, interstitial lung disease.
¶, Monoclonal Antibodies: bebtelovimab (n=7), sotrovimab (n=1); §, National Institutes of Health (NIH) COVID Ordinal Scale: 1) Not hospitalized and no limitations of activities 2) Not hospitalized, with limitation of activities, home oxygen (O2) requirement, or both 3) Hospitalized, not requiring supplemental O2 and no longer requiring ongoing medical care 4) Hospitalized, not requiring supplemental O2 but requiring ongoing medical care 5) Hospitalized, requiring any supplemental O2 6) Hospitalized, requiring noninvasive ventilation or use of high-flow O2 devices 7) Hospitalized, receiving invasive mechanical ventilation or extracorporeal membrane oxygenation 8) Death .